Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
16.65
-0.08 (-0.48%)
At close: Mar 28, 2025, 4:00 PM
16.62
-0.03 (-0.19%)
After-hours: Mar 28, 2025, 7:57 PM EDT
Tourmaline Bio Employees
Tourmaline Bio had 74 employees as of December 31, 2024. The number of employees increased by 30 or 68.18% compared to the previous year.
Employees
74
Change (1Y)
30
Growth (1Y)
68.18%
Revenue / Employee
n/a
Profits / Employee
-$989,324
Market Cap
427.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74 | 30 | 68.18% |
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRML News
- 17 days ago - Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 27 days ago - Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker - GlobeNewsWire
- 3 months ago - Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - GlobeNewsWire
- 4 months ago - Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - GlobeNewsWire
- 5 months ago - Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Tourmaline Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - GlobeNewsWire